PH12012500485A1 - Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof - Google Patents

Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof

Info

Publication number
PH12012500485A1
PH12012500485A1 PH1/2012/500485A PH12012500485A PH12012500485A1 PH 12012500485 A1 PH12012500485 A1 PH 12012500485A1 PH 12012500485 A PH12012500485 A PH 12012500485A PH 12012500485 A1 PH12012500485 A1 PH 12012500485A1
Authority
PH
Philippines
Prior art keywords
enzyme
compositions
modified opioid
opioid prodrugs
cleavable
Prior art date
Application number
PH1/2012/500485A
Other languages
English (en)
Inventor
Thomas E Enkins
Craig O Husfeld
Julie D Seroogy
Jonathan W Wray
Original Assignee
Signature Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signature Therapeutics Inc filed Critical Signature Therapeutics Inc
Publication of PH12012500485A1 publication Critical patent/PH12012500485A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
PH1/2012/500485A 2009-09-08 2010-04-21 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof PH12012500485A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24061109P 2009-09-08 2009-09-08
US28814809P 2009-12-18 2009-12-18
PCT/US2010/031956 WO2011031350A1 (en) 2009-09-08 2010-04-21 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof

Publications (1)

Publication Number Publication Date
PH12012500485A1 true PH12012500485A1 (en) 2012-10-22

Family

ID=43732738

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/500485A PH12012500485A1 (en) 2009-09-08 2010-04-21 Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof

Country Status (13)

Country Link
US (2) US9493477B2 (enExample)
EP (1) EP2475429B1 (enExample)
JP (3) JP2013503862A (enExample)
CN (1) CN102695545B (enExample)
AU (1) AU2010293028B2 (enExample)
BR (1) BR112012005124B1 (enExample)
CA (1) CA2773340C (enExample)
IL (1) IL218498A (enExample)
MX (1) MX348262B (enExample)
PH (1) PH12012500485A1 (enExample)
RU (1) RU2600736C2 (enExample)
SG (1) SG179026A1 (enExample)
WO (1) WO2011031350A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503862A (ja) * 2009-09-08 2013-02-04 シグネーチャー セラピューティクス，インク． 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20130059914A1 (en) 2010-04-21 2013-03-07 Signature Therapeutics, Inc. Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof
CA2795222A1 (en) * 2010-04-21 2011-10-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
SG184523A1 (en) 2010-05-10 2012-11-29 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
AU2012205733B2 (en) * 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
EP2683394B1 (en) 2011-03-09 2021-01-06 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers
JP5977355B2 (ja) * 2011-09-29 2016-08-24 エコール ノルマル シュペリウール ドゥ リヨン ペプチダーゼの蛍光発生基質
IN2014DN03009A (enExample) 2011-10-26 2015-05-08 Kempharm Inc
JP6232135B2 (ja) 2013-11-13 2017-11-15 ユーロ−セルティーク エス．エイ． 疼痛およびオピオイドによる腸機能障害症候群の治療のためのヒドロモルホンおよびナロキソン
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CA2969221C (en) 2014-12-02 2021-01-12 Travis Mickle Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods of making and use thereof
US11633492B2 (en) * 2017-11-24 2023-04-25 Byondis B.V. Process for the synthesis of linker-drug vc-seco-DUBA
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
US10807995B2 (en) 2018-07-13 2020-10-20 Alkermes Pharma Ireland Limited Thienothiophene compounds for long-acting injectable compositions and related methods
US10717712B2 (en) * 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
KR20230174213A (ko) 2021-03-09 2023-12-27 엔사이스 바이오사이언시즈 인크. 나파모스타트의 변형된 방출 조성물 및 그의 사용 방법
CN117715632A (zh) 2021-03-09 2024-03-15 恩赛斯生物科学股份有限公司 包含酶可裂解的前药和萘莫司他的组合物及其使用方法
CN113624665A (zh) * 2021-07-30 2021-11-09 中国药科大学 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法
MX2024003466A (es) 2021-09-29 2024-06-04 Ensysce Biosciences Inc Profarmacos de metadona escindibles por enzimas y metodos de uso de los mismos.

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527371B2 (en) 1980-09-16 1983-03-03 Torii & Co., Ltd. Amidine
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
CA2032420A1 (en) 1989-12-22 1991-06-23 Akira Okuyama Guanidinobenzene derivatives
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
EP0893437A4 (en) 1996-04-10 2000-12-27 Ono Pharmaceutical Co GUANIDINO TRYPTASE INHIBITOR
AU781255B2 (en) 1998-12-15 2005-05-12 Applied Biosystems, Llc Multiple enzyme assays
EP1161226B1 (en) * 1999-02-18 2004-05-26 SuperGen, Inc. Phosphocholine linked prodrug derivatives
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
ES2364452T3 (es) * 2001-06-11 2011-09-02 Medarex, Inc. Método para diseñar compuestos profármacos activados por cd10.
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7375082B2 (en) * 2002-02-22 2008-05-20 Shire Llc Abuse-resistant hydrocodone compounds
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
US20100092562A1 (en) 2002-11-26 2010-04-15 Hollenbeck R Gary Sustained-release drug delivery compositions and methods
JP4898445B2 (ja) 2003-05-29 2012-03-14 シャイア エルエルシー 乱用抵抗性アンフェタミン化合物類
EA008864B1 (ru) 2003-09-30 2007-08-31 Нью Ривер Фармасьютикалз Инк. Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
WO2005042773A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
FR2881363B1 (fr) * 2005-02-02 2008-03-14 Commissariat Energie Atomique Dispositif d'analyses biologiques avec detecteur integre
EP1928881A2 (en) * 2005-08-19 2008-06-11 Pharmacofore, Inc. Prodrugs of active agents
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
CN101309917B (zh) 2005-10-06 2013-09-11 奥斯拜客斯制药有限公司 具有增强治疗性质的胃h+，k+-atp酶氘代抑制剂
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
AU2007238858A1 (en) * 2006-04-10 2007-10-25 Shire Llc Mono and di-substituted oxycodone compounds and compositions
US20100144645A1 (en) 2006-04-14 2010-06-10 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse
SG172633A1 (en) 2006-05-26 2011-07-28 Pharmacofore Inc Controlled release of phenolic opioids
WO2008101202A1 (en) 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
WO2008101187A2 (en) 2007-02-16 2008-08-21 Pharmacofore, Inc. Pro-drugs of peripheral phenolic opioid antagonists
US9023860B2 (en) * 2007-11-26 2015-05-05 Signature Therapeutics, Inc. Pro-drugs for controlled release of biologically active compounds
WO2009080030A1 (en) 2007-12-21 2009-07-02 Lifecycle Pharma A/S Treatment of autoimmune hepatitis with a once daily oral dosage form comprising tacrolimus
WO2009092073A2 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects
JP2011512360A (ja) 2008-02-14 2011-04-21 アルカーメス，インコーポレイテッド 選択的オピオイド化合物
CA2723434C (en) 2008-05-05 2018-01-23 Oramed Ltd. Methods and compositions for oral administration of exenatide
CA2739936C (en) 2008-10-17 2017-12-12 Pharmacofore, Inc. Pharmaceutical compositions with attenuated release of phenolic opioids
CA2756397A1 (en) 2009-04-02 2010-10-07 Shire Llc Novel dicarboxylic acid linked amino acid and peptide prodrugs of opioids and uses thereof
EP2453900A1 (en) 2009-07-17 2012-05-23 Shire LLC Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof
JP2013503862A (ja) * 2009-09-08 2013-02-04 シグネーチャー セラピューティクス，インク． 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物
US20110262355A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
US20110262360A1 (en) 2010-04-21 2011-10-27 Jenkins Thomas E Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
WO2011133346A1 (en) 2010-04-21 2011-10-27 Pharmacofore, Inc. Peripheral opioid agonists and peripheral opioid antagonists
CA2795222A1 (en) * 2010-04-21 2011-10-27 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
AU2012205733B2 (en) * 2011-01-11 2015-10-08 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
WO2012096886A1 (en) * 2011-01-11 2012-07-19 Signature Therapeutics, Inc. Compositions comprising enzyme-cleavable oxycodone prodrug
EP2683394B1 (en) * 2011-03-09 2021-01-06 Signature Therapeutics, Inc. Active agent prodrugs with heterocyclic linkers
WO2012122420A2 (en) * 2011-03-09 2012-09-13 Pharmacofore, Inc. Opioid prodrugs with heterocyclic linkers

Also Published As

Publication number Publication date
CN102695545B (zh) 2016-08-17
JP6778234B2 (ja) 2020-10-28
US9493477B2 (en) 2016-11-15
JP2018172387A (ja) 2018-11-08
JP2016041698A (ja) 2016-03-31
IL218498A (en) 2017-03-30
BR112012005124B1 (pt) 2021-11-09
EP2475429A4 (en) 2013-04-03
SG179026A1 (en) 2012-04-27
MX348262B (es) 2017-06-05
CA2773340A1 (en) 2011-03-17
BR112012005124A2 (pt) 2020-08-25
WO2011031350A1 (en) 2011-03-17
EP2475429A1 (en) 2012-07-18
RU2012108874A (ru) 2013-09-20
IL218498A0 (en) 2012-07-31
US20120230916A1 (en) 2012-09-13
AU2010293028B2 (en) 2014-12-18
RU2600736C2 (ru) 2016-10-27
CN102695545A (zh) 2012-09-26
US10028945B2 (en) 2018-07-24
US20170119754A1 (en) 2017-05-04
MX2012002847A (es) 2012-08-23
HK1172283A1 (zh) 2013-04-19
CA2773340C (en) 2019-07-23
AU2010293028A1 (en) 2012-04-05
EP2475429B1 (en) 2015-07-29
JP2013503862A (ja) 2013-02-04

Similar Documents

Publication Publication Date Title
IL218498A0 (en) Compositions comprising enzyme- cleavable ketone - modified opioid prodrugs and optional inhibitors thereof
IL222354A0 (en) Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
AP3106A (en) Antiparisitic dihydroazole compounds and compositions comprising same
ZA201200054B (en) Therapeutic compounds and compositions
SG2014012462A (en) Pharmaceutical compositions
IL215057A (en) Pharmaceuticals for immediate release containing oxycodone and naloxone
EP2389068A4 (en) HEMGE OF THE HEDGEHOG SIGNAL PATH
HU0900072D0 (en) Transdermal pharmaceutical compositions
IL247086A0 (en) Nitrogen-containing compounds and pharmaceutical preparations
EP2519508A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
ZA201203012B (en) Solid pharmaceutical compositions containing an intergrase inhibitor
IL218937A0 (en) Pharmaceutical compositions comprising rivaroxaban
ZA201200079B (en) Pharmaceutical compositions and solid forms
GB0901494D0 (en) Compositions and Methods
SI2411376T1 (sl) INHIBITORJI NF-kB
IL220240A0 (en) Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
IL219018A0 (en) Pharmaceutical compositions
GB0902648D0 (en) Pharmaceutical compounds and compositions
GB0908317D0 (en) Pharmaceutical compounds and compositions
IL215486A0 (en) Compositions of cholinesterase inhibitors
HK1180899A (en) Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
EP2488624A4 (en) STABILIZED SURFACTANT-OXIDANT COMPOSITIONS AND METHODS THEREOF
GB0908069D0 (en) Pharmaceutical compounds and compositions
GB0903945D0 (en) Pharmaceutical compounds and compositions
GB0919055D0 (en) Pharmaceutical compounds and compositions